An exploratory study of sunitinib plus paclitaxel as firstline treatment for patients with advanced breast cancer

M. Kozloff, E. Chuang, A. Starr, P. A. Gowland, P. E. Cataruozolo, M. Collier, L. Verkh, X. Huang, K. A. Kern, Kathy Miller

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: Sunitinib has shown single-agent activity in patients with previously treated metastatic breast cancer (MBC). We investigated the safety of the combination of sunitinib and paclitaxel in an exploratory study of patients with locally advanced or MBC. Methods: Patients received oral sunitinib 25 mg/day (with escalation to 37.5 mg/day as tolerated) on a continuous daily dosing schedule and paclitaxel 90 mg/m 2 on days 1, 8, and 15 of each 28-day cycle. Study endpoints included safety (primary endpoint), pharmacokinetics, and antitumor activity. Results: Twenty-two patients were enrolled. The most frequent adverse events (AEs) were fatigue/asthenia (77%), dysgeusia (68%), and diarrhea (64%). Grade 3 AEs included neutropenia (43%), fatigue/asthenia (27%), neuropathy (18%), and diarrhea (14%). No drug-drug interaction was observed on the basis of pharmacokinetic analysis. Of 18 patients with measurable disease at baseline, 7 (38.9%) achieved objective responses (including 2 complete and 5 partial responses). Clinical responses were observed in three of nine patients with triple-negative receptor status (estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor-2 negative). Conclusions: These data indicate that sunitinib and paclitaxel in combination are well tolerated in patients with locally advanced or MBC. No drug-drug interaction was detected and there was preliminary evidence of antitumor activity.

Original languageEnglish
Pages (from-to)1436-1441
Number of pages6
JournalAnnals of Oncology
Volume21
Issue number7
DOIs
StatePublished - Dec 23 2009

Fingerprint

Paclitaxel
Breast Neoplasms
Asthenia
Drug Interactions
Therapeutics
Fatigue
Diarrhea
Pharmacokinetics
Dysgeusia
Safety
Progesterone Receptors
sunitinib
Neutropenia
Estrogen Receptors
Pharmaceutical Preparations
Appointments and Schedules

Keywords

  • Breast cancer
  • Paclitaxel
  • Sunitinib
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

An exploratory study of sunitinib plus paclitaxel as firstline treatment for patients with advanced breast cancer. / Kozloff, M.; Chuang, E.; Starr, A.; Gowland, P. A.; Cataruozolo, P. E.; Collier, M.; Verkh, L.; Huang, X.; Kern, K. A.; Miller, Kathy.

In: Annals of Oncology, Vol. 21, No. 7, 23.12.2009, p. 1436-1441.

Research output: Contribution to journalArticle

Kozloff, M, Chuang, E, Starr, A, Gowland, PA, Cataruozolo, PE, Collier, M, Verkh, L, Huang, X, Kern, KA & Miller, K 2009, 'An exploratory study of sunitinib plus paclitaxel as firstline treatment for patients with advanced breast cancer', Annals of Oncology, vol. 21, no. 7, pp. 1436-1441. https://doi.org/10.1093/annonc/mdp565
Kozloff, M. ; Chuang, E. ; Starr, A. ; Gowland, P. A. ; Cataruozolo, P. E. ; Collier, M. ; Verkh, L. ; Huang, X. ; Kern, K. A. ; Miller, Kathy. / An exploratory study of sunitinib plus paclitaxel as firstline treatment for patients with advanced breast cancer. In: Annals of Oncology. 2009 ; Vol. 21, No. 7. pp. 1436-1441.
@article{626bb962a8674ef29d05af18aa54ec78,
title = "An exploratory study of sunitinib plus paclitaxel as firstline treatment for patients with advanced breast cancer",
abstract = "Background: Sunitinib has shown single-agent activity in patients with previously treated metastatic breast cancer (MBC). We investigated the safety of the combination of sunitinib and paclitaxel in an exploratory study of patients with locally advanced or MBC. Methods: Patients received oral sunitinib 25 mg/day (with escalation to 37.5 mg/day as tolerated) on a continuous daily dosing schedule and paclitaxel 90 mg/m 2 on days 1, 8, and 15 of each 28-day cycle. Study endpoints included safety (primary endpoint), pharmacokinetics, and antitumor activity. Results: Twenty-two patients were enrolled. The most frequent adverse events (AEs) were fatigue/asthenia (77{\%}), dysgeusia (68{\%}), and diarrhea (64{\%}). Grade 3 AEs included neutropenia (43{\%}), fatigue/asthenia (27{\%}), neuropathy (18{\%}), and diarrhea (14{\%}). No drug-drug interaction was observed on the basis of pharmacokinetic analysis. Of 18 patients with measurable disease at baseline, 7 (38.9{\%}) achieved objective responses (including 2 complete and 5 partial responses). Clinical responses were observed in three of nine patients with triple-negative receptor status (estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor-2 negative). Conclusions: These data indicate that sunitinib and paclitaxel in combination are well tolerated in patients with locally advanced or MBC. No drug-drug interaction was detected and there was preliminary evidence of antitumor activity.",
keywords = "Breast cancer, Paclitaxel, Sunitinib, Tyrosine kinase inhibitor",
author = "M. Kozloff and E. Chuang and A. Starr and Gowland, {P. A.} and Cataruozolo, {P. E.} and M. Collier and L. Verkh and X. Huang and Kern, {K. A.} and Kathy Miller",
year = "2009",
month = "12",
day = "23",
doi = "10.1093/annonc/mdp565",
language = "English",
volume = "21",
pages = "1436--1441",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - An exploratory study of sunitinib plus paclitaxel as firstline treatment for patients with advanced breast cancer

AU - Kozloff, M.

AU - Chuang, E.

AU - Starr, A.

AU - Gowland, P. A.

AU - Cataruozolo, P. E.

AU - Collier, M.

AU - Verkh, L.

AU - Huang, X.

AU - Kern, K. A.

AU - Miller, Kathy

PY - 2009/12/23

Y1 - 2009/12/23

N2 - Background: Sunitinib has shown single-agent activity in patients with previously treated metastatic breast cancer (MBC). We investigated the safety of the combination of sunitinib and paclitaxel in an exploratory study of patients with locally advanced or MBC. Methods: Patients received oral sunitinib 25 mg/day (with escalation to 37.5 mg/day as tolerated) on a continuous daily dosing schedule and paclitaxel 90 mg/m 2 on days 1, 8, and 15 of each 28-day cycle. Study endpoints included safety (primary endpoint), pharmacokinetics, and antitumor activity. Results: Twenty-two patients were enrolled. The most frequent adverse events (AEs) were fatigue/asthenia (77%), dysgeusia (68%), and diarrhea (64%). Grade 3 AEs included neutropenia (43%), fatigue/asthenia (27%), neuropathy (18%), and diarrhea (14%). No drug-drug interaction was observed on the basis of pharmacokinetic analysis. Of 18 patients with measurable disease at baseline, 7 (38.9%) achieved objective responses (including 2 complete and 5 partial responses). Clinical responses were observed in three of nine patients with triple-negative receptor status (estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor-2 negative). Conclusions: These data indicate that sunitinib and paclitaxel in combination are well tolerated in patients with locally advanced or MBC. No drug-drug interaction was detected and there was preliminary evidence of antitumor activity.

AB - Background: Sunitinib has shown single-agent activity in patients with previously treated metastatic breast cancer (MBC). We investigated the safety of the combination of sunitinib and paclitaxel in an exploratory study of patients with locally advanced or MBC. Methods: Patients received oral sunitinib 25 mg/day (with escalation to 37.5 mg/day as tolerated) on a continuous daily dosing schedule and paclitaxel 90 mg/m 2 on days 1, 8, and 15 of each 28-day cycle. Study endpoints included safety (primary endpoint), pharmacokinetics, and antitumor activity. Results: Twenty-two patients were enrolled. The most frequent adverse events (AEs) were fatigue/asthenia (77%), dysgeusia (68%), and diarrhea (64%). Grade 3 AEs included neutropenia (43%), fatigue/asthenia (27%), neuropathy (18%), and diarrhea (14%). No drug-drug interaction was observed on the basis of pharmacokinetic analysis. Of 18 patients with measurable disease at baseline, 7 (38.9%) achieved objective responses (including 2 complete and 5 partial responses). Clinical responses were observed in three of nine patients with triple-negative receptor status (estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor-2 negative). Conclusions: These data indicate that sunitinib and paclitaxel in combination are well tolerated in patients with locally advanced or MBC. No drug-drug interaction was detected and there was preliminary evidence of antitumor activity.

KW - Breast cancer

KW - Paclitaxel

KW - Sunitinib

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=77950538734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950538734&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdp565

DO - 10.1093/annonc/mdp565

M3 - Article

C2 - 20032126

AN - SCOPUS:77950538734

VL - 21

SP - 1436

EP - 1441

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -